{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-223292","form_type":"8-K","ticker":"SEPN","cik":"0001984086","company_name":"Septerna, Inc.","filed_at":"2025-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.761639+00:00","generated_at":"2026-05-17T05:27:48.621122+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Septerna appoints Keith Gottesdiener, M.D. to board as Class I director and R&D Committee chair","bullets":["Appointment effective Sept 25; board expanded to eight; Gottesdiener serves three-year term until 2028.","Also appointed to Compensation Committee and as chair of newly constituted R&D Committee effective Sept 26.","Gottesdiener is independent under Nasdaq/SEC rules; no material transactions or family relationships with officers.","Compensation per standard non-employee director policy plus $12,000 annual retainer for R&D Committee chair.","Former CEO of Prime Medicine and Rhythm Pharmaceuticals; 16 years at Merck with over 20 drug approvals."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-223292","json":"https://secwatch.observer/filing/0001193125-25-223292.json","markdown":"https://secwatch.observer/filing/0001193125-25-223292.md","text":"https://secwatch.observer/filing/0001193125-25-223292.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1984086/000119312525223292/0001193125-25-223292-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1984086/000119312525223292/d942032d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:27:48.621122+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}